RBM4 and cancer: In addition, only certain cancers are sensitive to GLS inhibition, but current knowledge on biomarkers for selection of patients with tumors dependent on glutamine pathway is poor, which have hindered effective clinical application of GLS inhibitors.99–101 Herein, our study showed that ESCC cells were more sensitive to glutamine pathway inhibition relative to normal esophageal epithelial cells, and the ESCC cells with aberrant expression of RBM4 exhibit higher glutamine dependency, offering the therapeutic potential of targeting glutaminolysis.